Skip to main content
SCLX
NASDAQ Life Sciences

Scilex Holding Co. Revokes Preferred Stock Dividend, Eliminates Series 1 Preferred Shares

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$8.81
Mkt Cap
$74.808M
52W Low
$3.6
52W High
$34.27
52W Position info
145% above low
Off High info
74% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

SCLX has more than doubled off its 52-week low of $3.6.

Summary

Scilex Holding Co. has revoked a long-delayed preferred stock dividend and eliminated the associated Series 1 Mandatory Exchangeable Preferred Stock, simplifying its capital structure.


Key Events · Corporate Governance and Compliance · SCLX

  • Dividend Revocation Approved

    The Board of Directors formally approved the revocation of a previously declared stock dividend consisting of 5,000,000 shares of Series 1 Mandatory Exchangeable Preferred Stock.

  • Preferred Stock Designation Eliminated

    A Certificate of Elimination was filed with the State of Delaware, removing the designation of Series 1 Mandatory Exchangeable Preferred Stock and returning these shares to undesignated status.

  • Capital Structure Clarified

    No Series 1 Preferred Stock was ever issued, and this action removes a potential future dilutive overhang, providing clarity to the company's capital structure.


Analysis · SCLX · Life Sciences

Scilex Holding Company's Board of Directors has officially revoked a previously declared stock dividend of 5,000,000 shares of Series 1 Mandatory Exchangeable Preferred Stock. This dividend, initially declared in October 2024, had faced multiple postponements and was never issued. The subsequent filing of a Certificate of Elimination formally removes the designation of these preferred shares, returning them to undesignated status. This action clarifies the company's capital structure and removes a long-standing potential source of future dilution, which could be viewed positively by investors seeking certainty. This follows closely on the heels of a significant strategic investment announced yesterday, suggesting a broader effort to streamline capital management.

At the time of this filing, SCLX was trading at $8.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $74.8M. The 52-week trading range was $3.60 to $34.27. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SCLX - Latest Insights

SCLX
Jul 22, 2026, 5:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.03
Real-time Price: $6.89 info
Change: -$0.140 (-2%) info
Market Cap: $59.694M info
SCLX
Jul 07, 2026, 9:26 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $9.50
Real-time Price: $6.89 info
Change: -$2.61 (-27%) info
Market Cap: $59.694M info
SCLX
Jul 06, 2026, 6:15 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $9.08
Real-time Price: $6.89 info
Change: -$2.19 (-24%) info
Market Cap: $59.694M info
SCLX
Jun 29, 2026, 5:01 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $7.80
Real-time Price: $6.89 info
Change: -$0.910 (-12%) info
Market Cap: $59.694M info
SCLX
Jun 24, 2026, 4:52 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.86
Real-time Price: $6.89 info
Change: +$0.030 (+0.44%) info
Market Cap: $59.694M info